Latest news, reports, and more from the RedChip Nation.
 
Discovering Tomorrow's Blue Chips Today
March 23, 2021     Contact    
Featured This Week
 
Reviva Pharmaceuticals (Nasdaq: RVPH)
 

 

RedChip is pleased to welcome its newest client, Reviva Pharmaceuticals. Trading on Nasdaq under the ticker RVPH, Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva reported encouraging results from its successfully completed Phase 1b study in stable schizophrenia patients and from its large Phase 2 study for RP5063 in acute schizophrenia and schizoaffective disorder patient population. The Company is now preparing to initiate a Phase 3 study in acute schizophrenia patients. Learn more at RVPHinfo.com.

 
 >
Latest News
 
Annovis Bio (NYSE American: ANVS) Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
 >
Can-Fite BioPharma (NYSE American: CANF) Signs $42.7 Million Out-Licensing Deal with Ewopharma
 >
Lantern Pharma (NASDAQ: LTRN) ) Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties
 
 
Nano Dimension (NASDAQ: NNDM) First Ever Additively Manufactured Electronic (AME) Monolithic RF Communications Circuit Has Been Sent to International Space Station (ISS) Flight Studies
 
 
SPI Energy’s (NASDAQ: SPI) Partners with Common Energy to Connect New Community Solar Projects to the Oregon Electrical Grid
 
 
Hoth Therapeutics (NASDAQ: HOTH) Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006
 
 
American Resources (NASDAQ: AREC) Strengthens Team with Appointment of Well-Established Industry Executive to Oversee American Carbon Subsidiary
 
 
Elixinol (OTCQB: ELLXF) to Acquire 100% of CannaCare Health
 
 
Recruiter.com (OTCQB: RCRT) Partners with QuickFee, Bringing Flexible Online Payment Solutions to More than 800,000 Recruiting and HR Professionals
 
 
BTCS (OTCQB: BTCS) Ethereum 2.0 Staking Operation Producing Revenues From All 200 Nodes
 
 
Alset EHome International (NASDAQ: AEI) Completes Previously Announced Investments in Alset International, LiquidValue Development, True Partners Capital, and American Pacific Bancorp
 
 
Bragg Gaming (OTC: BRGGF) Enters Switzerland with Grand Casino Luzern
 
 
SinglePoint’s (OTC: SING) Secures $2,000,000 in Accretive Financing to Drive Recent Acquisitions
 
 
DSG Global (OTCQB: DSGT) Expands EV Lineup with Two New Models Available in the Second Quarter
 
 
 
Upcoming Zoom Webinar
 

Join Zoom Meeting: zoom.us/j/99903872822
One tap mobile
US: +13126266799,,99903872822#,,,,*026093# or
+16465588656,,99903872822#,,,,*026093#
Or Telephone:
Dial(for higher quality, dial a number based on your current location):
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington D.C)
+1 312 626 6799 US (Chicago)
+1 669 900 9128 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)

Webinar ID: 999 0387 2822
Passcode: 026093
International numbers available:
zoom.us/u/abHxCjkG30


 
 
 

Join Zoom Meeting: zoom.us/j/96435395404
One tap mobile
US: +16465588656,,96435395404#,,,,*920945# or
+13017158592,,96435395404#,,,,*920945#
Or Telephone:
Dial(for higher quality, dial a number based on your current location):
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington D.C)
+1 312 626 6799 US (Chicago)
+1 669 900 9128 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)

Webinar ID: 964 3539 5404
Passcode: 920945
International numbers available:
zoom.us/u/ac3dzvHM6o


 
 
 

Join Zoom Meeting: zoom.us/j/97339978143
One tap mobile
US: +13017158592,,97339978143# or
+13126266799,,97339978143#
Or Telephone:
Dial(for higher quality, dial a number based on your current location):
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington D.C)
+1 312 626 6799 US (Chicago)
+1 669 900 9128 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)

Webinar ID: 973 3997 8143
International numbers available:
zoom.us/u//aqTpQiuF4


 
 
 

Join Zoom Meeting: zoom.us/j/97854930812
One tap mobile
US: +13126266799,,97854930812#,,,,*623264# or
or +16465588656,,97854930812#,,,,*623264#
Or Telephone:
Dial(for higher quality, dial a number based on your current location):
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington D.C)
+1 312 626 6799 US (Chicago)
+1 669 900 9128 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)

Webinar ID: 978 5493 0812
Passcode: 623264
International numbers available:
zoom.us/u/ac33XYTF8


 
 
 
 
 
Quote of the Week
 
"Be wary of bad management teams, don’t bet on dreams. Do your homework and be careful."
- Dave Maley, Manager Ariel Discovery Fund
 
 
 
Lesson of the Week
 
The key to successful microcap investing is diversification.
Read More
 
 
 

 

Latest Videos
 
 
This Week on RedChip TV: Two Biotech’s Entering Phase 3 Trials in 2021
 
This week features two interviews with Hoth Therapeutics (NASDAQ: HOTH) and Can-Fite BioPharma (NYSE AMERICAN: CANF), two exciting biotechs preparing to launch Phase 3 trials in 2021.
 
Watch Now
 
 
 
 
COMSovereign Corporate Overview with CEO & CTO
 
COMSovereign Holding (Nasdaq: COMS) Chairman & CEO Dan Hodges, along with Chief Technology Officer Dr. Dustin McIntire, share insight into the Company’s portfolio of communications technology companies and how they are expected to drive rapid growth in 2021 and beyond. Through strategic acquisitions and organic research and development efforts, COMSovereign has become a U.S.-based communications provider able to provide 4G LTE Advanced and 5G-NR telecom solutions to network operators and enterprises.
 
Watch Now
 
 
 
 
Hoth Therapeutics: Developing a New Generation of Therapies for Unmet Medical Needs
 
Hoth Therapeutics (Nasdaq: HOTH) is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's clinical pipeline is concentrated on drug candidates that improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia.
 
Watch Now
 
 
 
 
Can-Fite BioPharma: Advanced Clinical Stage Drug Development
 
Can-Fite BioPharma (NYSE American: CANF) has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases. The company’s platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention.
 
Watch Now
 
 
 
 
Esports Entertainment Group CEO Discusses Plans for Rapid Growth
 
Interview with CEO of Esports Entertainment Group Inc. (NASDAQ: GMBL), a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Its mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports.
 
Watch Now
 
 
 
 
Alset EHome International: Diversified Operations Accelerating Sustainable Healthy Living
 
Alset EHome International (Nasdaq: AEI) is a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities with operations in the United States, Singapore, Hong Kong, Australia and South Korea.
 
Watch Now
 
 
 
 
CBD of Denver: Corporate Overview
 
CBD of Denver (OTC: CBDD) is a full-line CBD and hemp oil company, producing and distributing cannabis and CBD products in Switzerland, Europe, and the US. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for its shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
 
Watch Now
 
 
 
 
Amesite (NASDAQ: AMST) Star Pupil in the EdTech Space
 
Amesite is an ed-tech, SaaS company with the most advanced artificial intelligence driven online learning platform in the industry, providing both content creation and a best-in-class infrastructure for the multi-billion-dollar online learning markets in business and education.
 
Watch Now
 
 
 
 
BTCS: Pioneer in Blockchain Space with Near-Term Revenue Growth
 
BTCS (OTCQB: BTCS) is an early entrant in the digital asset market and one of the first U.S. publicly traded companies focused on digital assets and blockchain technologies. The Company through its transaction verification services business actively verifies and validates blockchain transactions and is rewarded with digital assets for its work.
 
Watch Now
 
 
 
 
Nano Dimension: CEO Discusses Acquisition Strategy
 
Nano Dimension (NASDAQ: NNDM) is a provider of intelligent machines for the fabrication of Additively Manufactured Electronics (AME). High fidelity active electronic and electromechanical subassemblies are integral enablers of autonomous intelligent drones, cars, satellites, smartphones, and in vivo medical devices.
 
Watch Now
 
 
 
 
American Resources: Next-Generation Raw Materials Supplier for New Infrastructure
 
American Resources Corp. (Nasdaq: AREC) is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical rare earth minerals for the electrification market, and reprocessed metal to be recycled.
 
Watch Now
 
 
 
 
Draganfly: Drone Technology Solving Real World Challenges
 
Draganfly (OTCQB: DFLYF) has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live.
 
Watch Now
 
 
 
 
Genetic Technologies: Innovative Tests to Determine Disease Risk
 
Genetic Technologies (Nasdaq: GENE) is a diversified molecular diagnostics company developing tools for the prediction and assessment of cancer risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company’s development pipeline includes new tests for COVID-19, Type 2 diabetes, cardiovascular disease, prostate cancer, and melanoma.
 
Watch Now
 
 
 
 
CBD of Denver: High-Growth Business Targeting US and Europe
 
CBD of Denver (OTC: CBDD) is a full-line CBD and hemp oil company, producing and distributing cannabis and CBD products in Switzerland, Europe, and the US. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for its shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
 
Watch Now
 
 
 
 
Amesite: Award-Winning AI-Driven Learning for Institution
 
Amesite (Nasdaq: AMST) is a high-tech artificial intelligence (AI) software company offering a cloud-based platform and content creation services for K-12, college, university and business education and upskilling. Amesite-offered courses and programs are branded to its customers.
 
Watch Now
 
 
 
 
BioVie: Developing Potential Game-Changing Treatments for Liver Disease
 
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS).
 
Watch Now
 
 
 
 
DSG Global: Positioned for Rapid Growth in Electric Vehicle Market
 
DSG Global (OTCQB: DSGT) is an emerging global technology company with an array of interconnecting businesses in some of the fastest growing market sectors.
 
Watch Now
 
 
 
 
Small-Cap NASDAQ Solar Company Positioned for Rapid Growth
 
Delivering competitive, clean energy solutions to customers for more than 15 years, SPI Energy (NASDAQ: SPI) is an established renewable energy player with global operations in key markets in Asia, Australia, North America, and Europe.
 
Watch Now
 
 
 
 
Kiromic BioPharma: AI-Powered Drug Discovery and Development
 
Kiromic BioPharma (Nasdaq: KRBP) is revolutionizing next-generation allogenic CAR therapies for solid tumors. The Company’s proprietary target discovery engine, Diamond uses AI and a proprietary neural network to identify development targets, dramatically compressing man years and billions of drug development dollars required to develop new live drugs.
 
Watch Now
 
 
 
 
CEO Interview with OLB Group: High-Growth Fintech Company on the Move
 
The OLB Group (NASDAQ: OLB) is led by a team of seasoned industry executives with extensive experience in payments, ecommerce, and mobile commerce. Trading at 3x sales, upside could be significant in an industry where peer comps trade as high as 39x sales. Aegis Capital gave OLB a buy rating and $9 price target in its latest report on the Company. Learn more at OLBGinfo.com.
 
Watch Now
 
 
 
 
Tiziana Life Sciences: CEO Discusses Positive Data from COVID-19 Trial
 
Tiziana Life Sciences (Nasdaq: TLSA) is a clinical stage biotechnology company focused on the discovery and development of novel molecules to treat human disease in oncology and immunology. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets.
 
Watch Now
 
 
 
 
Greenwich LifeSciences: Phase 3 Targeting Recurrent Breast Cancer
 
Greenwich LifeSciences (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
 
Watch Now
 
 
 
 
Bragg Gaming: Technology Infrastructure for the Global Gaming Industry
 
Bragg Gaming Group Inc. (OTC: BRGGF) is a next generation gaming group with cutting-edge technology, leading brands and world-class management expertise, developing into a global gaming force. Formed by a team of gaming industry experts, Bragg's main portfolio is ORYX Gaming, an innovative B2B gaming technology platform and casino content aggregator.
 
Watch Now
 
 
 
 
RYU Apparel: Award-Winning Urban Athletic Brand
 
RYU Apparel (OTC: RYPPF) is an award winning urban athletic apparel brand that engages in the development, marketing, and distribution of apparel, bags and accessories. Our products are engineered for the fitness, training and performance of the multi-discipline athlete.
 
Watch Now
 
 
 
 
Order Small Stocks, Big Money Today!
 
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
 
 
MidSouth Week in Review
 
The Dow, S&P and Russell 2000 all made new highs again last week.
Read More
 
 
 
 
About RedChip
 
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
 
RedChip Disclosure
 
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures.
 
 
     
 
 
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.